Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | GPR174 | Q9BXC1 | 2/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | CCR6 | P51684 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1274938 | 0.84 | HTT (0.73) | MAPTKMT2AMAPK1HTTALDH1A1 | |
| SCHEMBL30784064 | 0.84 | MAPT (0.60) | MAPTKMT2AMAPK1HTTALDH1A1 | |
| SCHEMBL11507421 | 0.84 | HTT (0.56) | MAPTKMT2AMAPK1HTTALDH1A1 | |
| SCHEMBL3436179 | 0.84 | KMT2A (0.56) | MAPTKMT2AMAPK1HTTALDH1A1 | |
| SCHEMBL28799318 | 0.83 | KMT2A (0.56) | MAPTKMT2AMAPK1HTTALDH1A1 | |
| SCHEMBL30921265 | 0.82 | HTT (0.66) | MAPTKMT2AMAPK1HTTALDH1A1 | |
| SCHEMBL7061229 | 0.82 | MAPT (0.63) | MAPTKMT2AMAPK1HTTALDH1A1 | |
| SCHEMBL23043784 | 0.81 | HTT (0.54) | MAPTKMT2AMAPK1HTTALDH1A1 | |
| SCHEMBL3799173 | 0.81 | CTSB (0.65) | MAPTKMT2AMAPK1HTTALDH1A1 | |
| SCHEMBL29937743 | 0.81 | CTSB (0.65) | MAPTKMT2AMAPK1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732382-B2 | Photodamage mitigation compounds and systems | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20150079603-A1 | PHOTODAMAGE MITIGATION COMPOUNDS AND SYSTEMS | PACIFIC BIOSCIENCES CALIFORNIA (US) | 2015-03-19 | — | — | US | disclosed |
| US-8834847-B2 | Photodamage mitigation compounds and systems | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120052488-A1 | PHOTODAMAGE MITIGATION COMPOUNDS AND SYSTEMS | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| EP-2228364-A1 | Acylsulfonamides as inhibitors of steroid sulfatase | Novartis AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | MEINGASSNER JOSEF GOTTFRIED | 2009-09-10 | — | — | US | disclosed |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | MEINGASSNER JOSEF GOTTFRIED | 2009-09-10 | — | — | US | disclosed |
| US-7482462-B2 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2009-01-27 | — | — | US | disclosed |
| US-7482462-B2 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2009-01-27 | — | — | US | disclosed |
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| WO-2006097293-A2 | COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | STS, ARSA, CYP17A1 | MAPT 3209/4885KMT2A 2981/4885MAPK1 3743/4885 |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | STS, SERPINB1, MPO | MAPT 3544/4885KMT2A 4156/4885MAPK1 2555/4885 |
| US-20120052488-A1 | PHOTODAMAGE MITIGATION COMPOUNDS AND SYSTEMS | CRY1, ERCC1, ERCC4 | MAPT 518/4885KMT2A 2469/4885MAPK1 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.